

Alaska Medicaid

Zyvox® (linezolid)

Available 600mg tablets and 100mg/5ml oral suspension

INDICATIONS:

“ZYVOX formulations are indicated in the treatment of the following infections caused by susceptible strains of the designated microorganism . Linezolid is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected.

Vancomycin-Resistant *Enterococcus faecium* infections, including cases with concurrent bacteremia.

Nosocomial pneumonia caused by *Staphylococcus aureus* (methicillin-susceptible and-resistant strains), or *Streptococcus pneumoniae* (including multi-drug resistant strains[MDRSP]).

Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by *Staphylococcus aureus* (methicillin-susceptible and -resistant strains), *Streptococcus pyogenes*, or *Streptococcus agalactiae*. ZYVOX has not been studied in the treatment of decubitus ulcers.

Uncomplicated skin and skin structure infections caused by *Staphylococcus aureus* (methicillin-susceptible only) or *Streptococcus pyogenes*.

Community-acquired pneumonia caused by *Streptococcus pneumoniae* (including multidrug resistant strains [MDRSP]*), including cases with concurrent bacteremia, or *Staphylococcus aureus* (methicillin-susceptible strains only).”¹

Criteria for Approval:

1. Zyvox not to be used as empiric or first-line treatment; **AND**
2. Antibiotic resistance is demonstrated by culture and susceptibility testing; **AND**
3. Diagnosis of one of the above approved FDA indications.

Length of Authorization:

Prior authorization may be approved for up to 14 days. For vancomycin-resistant Enterococcus may be approved up to 28 days.

Dispensing Limit:

The dispensing limit is 28 tablets or 900ml of the oral suspension. For vancomycin-resistant Enterococcus is 56 tablets or 1800ml of the oral suspension.

References:

¹ Zyvox® package insert is available at:

< <http://labeling.pfizer.com/showlabeling.aspx?id=649> > Accessed 12/07/11

Zyvox criteria

Version 1

Last updated 12/08/2011

Approved 1/20/2012